经济观察网浩希健康科技(HAO.US)发布最新财报，显示营业收入为3280万美元，净利润为388万美元， 每股收益1.66美元，市盈率为0.81倍。公司业务高度依赖在线广告营销行业，近期医疗保健数字广告趋 势波动可能影响股价。 财报分析 浩希健康科技最新财报显示，营业收入3280万美元，净利润388万美元，每股收益1.66美元，市盈率0.81 倍。公司主要收入来源于一站式在线营销解决方案，业务聚焦医疗保健行业数字广告。财报数据反映近 期经营表现，但行业波动性较高，需关注在线广告政策变化及技术发展影响。 以上内容基于公开资料整理，不构成投资建议。 股票近期走势 近7天(2026年2月9日至12日)，浩希健康科技股价波动显著。具体表现为：2月9日收盘价1.21美元，单日 上涨10.00%；2月10日收盘价1.23美元，上涨1.65%；2月11日收盘价1.24美元，上涨0.81%；2月12日收 盘价1.23美元，下跌0.81%。区间累计涨幅11.82%，振幅达29.09%，成交额约5.99万美元，换手率较 低。同期，所属广告营销板块下跌17.72%，美股大盘道指涨1.11%、纳指涨0.25%，公司股价表现相对 独立 ...

经济观察网 浩希健康科技（HAO.us）近期发布了最新财报，显示其营业收入为3280万美元，净利润为 388万美元，每股收益1.66美元，市盈率为0.81倍。 业绩经营情况 根据最新披露的财报数据，公司营业收入为32.80百万美元，净利润为3.88百万美元，每股收益1.66美 元，市盈率为0.81倍。这些数据反映了公司近期的经营表现。 行业政策与环境 公司业务高度依赖在线广告营销行业，尤其是医疗保健领域的数字广告趋势。近期行业整体波动较大， 例如广告营销板块出现下跌，可能影响公司股价。此外，医疗AI应用等技术发展可能间接波及公司业 务。 以上内容基于公开资料整理，不构成投资建议。 ...

Business Operations - The operating entity served approximately 2,000 advertisers since its incorporation in 2018, with 473, 543, and 393 advertiser customers in the fiscal years ended June 30, 2025, 2024, and 2023, respectively [24]. - The majority of advertisers are healthcare companies, with 414, 471, and 341 healthcare companies served in the same fiscal years [24]. - The operating entity's revenue generation is primarily through one-stop online marketing solutions, particularly online short video marketing solutions [24]. - The company is focused on reducing costs and increasing efficiency for its advertisers, responding to the growing demand for personalized services in the healthcare sector [24]. - A substantial majority of the company's revenue is derived from online marketing services provided to healthcare industry advertisers, which are dependent on maintaining relationships with these advertisers [129]. - The company may face challenges in maintaining relationships with advertisers, which could adversely affect revenue and profitability [145]. - The company is subject to PRC laws that restrict the payment of dividends, requiring companies to set aside at least 10% of after-tax profits for statutory reserves [124]. - The company may experience net cash outflow from operating activities, impacting its ability to maintain sufficient net cash inflows [140]. Financial Performance - Total revenue decreased by $15.72 million, or 32.39%, to $32.80 million for the fiscal year ended June 30, 2025, compared to $48.52 million for the fiscal year ended June 30, 2024 [146]. - The company served 473 advertiser customers in the fiscal year ended June 30, 2025, which is a decrease of 70 customers from the previous fiscal year [146]. - Net income for the fiscal year ended June 30, 2025, was $3.88 million, an increase of $2.58 million from $1,292,054 for the fiscal year ended June 30, 2024 [146]. - The five largest customers accounted for 27.32%, 21.06%, and 36.81% of total revenue for the fiscal years ended June 30, 2025, 2024, and 2023, respectively [144]. - The average revenue per customer increased from $66,489 for the fiscal year ended June 30, 2022, to $71,830 for the fiscal year ended June 30, 2023 [175]. - Revenue generated from online marketing and digital advertising services increased by $12,072,284 from the fiscal year ended June 30, 2022, to the fiscal year ended June 30, 2023 [175]. - Revenue generated from online marketing and digital advertising services decreased to $32,804,336 for the fiscal year ended June 30, 2025 [175]. Regulatory Environment - The PRC Foreign Investment Law, effective January 1, 2020, introduces uncertainties regarding foreign investment regulations that may impact the operating entity's business [26]. - The company is not currently subject to cybersecurity reviews under the Cybersecurity Review Measures, as its business does not involve processing users' personal information [26]. - The CSRC's filing requirements could impose risks, including fines ranging from RMB 1 million to RMB 10 million for non-compliance, potentially affecting the company's ability to offer securities [27]. - The company has not received any inquiries or sanctions regarding its overseas listing from the CSRC or other PRC authorities as of the report date [30]. - The company is monitoring regulatory developments related to overseas listings and may face significant uncertainties regarding compliance with new regulations [86]. - The PRC government may strengthen oversight over overseas offerings and foreign investments, potentially impacting the company's operations and securities offerings [54]. - The interpretation and implementation of the PRC Foreign Investment Law remain uncertain, which could affect the company's corporate governance and business operations [56]. Investment and Capital Structure - The company completed the required filing procedures for its initial public offering (IPO) on September 14, 2023, as mandated by the CSRC's Overseas Listing Trial Measures [27]. - The company completed its IPO on January 30, 2024, raising total gross proceeds of $11,040,000 from the sale of 2,760,000 Class A Ordinary Shares [141]. - The follow-on offering on September 20, 2024, generated gross proceeds of $12,000,000 from the sale of 4,000,000 units, each priced at $3.00 [141]. - Future issuances of Class A Ordinary Shares could result in substantial dilution for existing shareholders, adversely affecting the market price [201]. - The anticipated public float may lead to extreme volatility in the trading price of Class A Ordinary Shares, making it difficult for investors to assess their value [200]. - The company does not intend to pay dividends for the foreseeable future [221]. - Future earnings are intended to be retained to finance business operations and expansion [221]. Risks and Challenges - The company faces risks related to the PRC government's influence over business operations, which could materially affect financial conditions and results [37]. - The company may face difficulties in transferring cash or assets out of the PRC due to government restrictions, impacting liquidity and operational funding [33]. - The company is exposed to risks from its reliance on a major supplier, Ocean Engine, and any deterioration in this relationship could adversely affect financial performance [38]. - The company may face challenges in maintaining relationships with media partners, which could adversely affect its access to advertising channels and revenue [136]. - The company may incur substantial costs to comply with new cybersecurity regulations, which could materially affect its business operations and financial position [52]. - The company may face litigation risks due to increased visibility from public disclosures, which could harm its business and operating results [217]. Internal Controls and Governance - The company has identified material weaknesses in its internal controls over financial reporting (ICFR), including a lack of experienced staff and monitoring mechanisms [207]. - The CEO, Mr. Zhen Fan, holds 75.14% of the voting rights due to the dual-class share structure, which may lead to decisions not aligned with the interests of other shareholders [212]. - The company plans to implement remedial measures for identified weaknesses in ICFR, which may incur significant costs but may not fully resolve the issues [210]. - The company is still in the process of obtaining liability insurance for its directors and officers, which may be more expensive due to public company status [218].

Exhibit 99.1 HAOXI HEALTH TECHNOLOGY LIMITED INDEX TO CONSOLIDATED FINANCIAL STATEMENTS | CONTENTS | PAGE(S) | | --- | --- | | CONSOLIDATED FINANCIAL STATEMENTS | | | CONDENSED UNAUDITED CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2024 AND JUNE 30, | | | 2024 | F-2 | | CONDENSED UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE | | | INCOME (LOSS) FOR THE SIX MONTHS ENDED DECEMBER 31, 2024 AND 2023 | F-3 | | CONDENSED UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS | | ...

Core Insights - Haoxi Health Technology Limited has launched a customized livestreaming agency strategy through its subsidiary, Haoxi Beijing, to enhance its business development in the healthcare sector [1][4] - The new livestreaming services are designed to meet the growing demand for personalized and high-quality offerings in the medical aesthetics market, particularly focusing on "light medical aesthetics" treatments [2][4] Company Overview - Haoxi Health Technology Limited is an online marketing solution provider based in Beijing, specializing in the healthcare industry, and aims to reduce costs and increase efficiency for advertisers [5] - The company has established a stable advertising delivery model based on long-term client servicing experience, which supports its new service offerings [2][5] Service Details - The livestreaming agency services encompass a full-cycle approach, including pre-campaign planning, livestream initiation, and post-campaign analysis, tailored for the medical aesthetics segment [2][4] - The services include account setup, content planning, short video marketing, livestream ad strategy, and platform resource integration, aimed at enhancing brand building and online conversion rates [4]

Core Points - Haoxi Health Technology Limited has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its Class A ordinary shares maintained a minimum bid price of $1.00 for 10 consecutive business days [1][2] - The compliance determination was made following the closing bid price of the Company's Ordinary Shares being at or above $1.00 from January 27, 2025, to February 7, 2025 [2] Company Overview - Haoxi Health Technology Limited is an online marketing solution provider based in Beijing, China, focusing on the healthcare industry [3] - The Company specializes in online short video marketing and offers one-stop online marketing solutions to help advertisers acquire and retain customers on popular Chinese platforms such as Toutiao, Douyin, WeChat, and Sina Weibo [3] - The growth of the Company is driven by the rise of news feed ads and the rapid development of the healthcare sector, with a commitment to reducing costs and increasing efficiency for advertisers [3]

Core Viewpoint - Haoxi Health Technology Limited has announced a reverse share split of its ordinary shares at a ratio of 1-for-25, which was approved by shareholders and will take effect on January 27, 2025 [1][2]. Group 1: Reverse Share Split Details - The reverse share split will combine every 25 shares of Class A and Class B ordinary shares into one share, reducing the total outstanding Class A shares from approximately 53.29 million to about 2.13 million and Class B shares from approximately 17.27 million to about 0.69 million [2]. - The company's Articles and Memorandum of Association have been amended to proportionately reduce the number of authorized shares and adjust the par value of the post-reverse share split ordinary shares to $0.0025 per share [3]. - No fractional shares will be issued; instead, entitlements to fractional shares will be rounded up to the nearest whole share [3]. Group 2: Market Impact and Expectations - Following the reverse share split, the Class A ordinary shares are expected to trade at approximately twenty-five times the price per share prior to the split, although the company cannot guarantee that this price will be maintained [4]. - The new CUSIP number for the Class A ordinary shares will be G4290F118, and trading will commence on an adjusted basis on the Nasdaq Capital Market [1][2]. Group 3: Company Overview - Haoxi Health Technology Limited is an online marketing solution provider based in Beijing, China, focusing on the healthcare industry [6]. - The company's growth is driven by the rise of news feed ads and the rapid development of the healthcare sector, offering one-stop online marketing solutions, particularly in online short video marketing [6].

Core Insights - Haoxi Health Technology Limited has secured a Recharge Service Framework Contract worth RMB30 million with Tengyuan Media Advertising Co., Ltd to provide comprehensive digital advertising services [1][2][3] - The partnership is seen as a significant milestone in the company's strategic roadmap, aimed at enhancing service capabilities and market position [3] Company Overview - Haoxi Health Technology Limited is an online marketing solution provider based in Beijing, specializing in the healthcare industry [4] - The company focuses on one-stop online marketing solutions, particularly in online short video marketing, leveraging popular platforms in China such as Toutiao, Douyin, WeChat, and Sina Weibo [4] - The growth of the company is driven by the rise of news feed ads and the rapid development of the healthcare sector [4] Contract Details - The contract allows Beijing Haoxi to produce customized internet marketing services tailored to Tengyuan's business needs [2] - Over the next year, Beijing Haoxi will utilize its marketing expertise to promote and enhance competitiveness for Tengyuan and its clients [2] Strategic Importance - The CEO of Haoxi Health Technology Limited emphasized that the contract brings significant economic benefits and supports the company's transformation into the digital marketing industry [3] - The collaboration is expected to drive innovation and growth within the industry [3]

Core Viewpoint - Haoxi Health Technology Limited reported significant financial growth for the fiscal year ended June 30, 2024, with net revenue increasing by 72% to $48.52 million, driven by a rise in average revenue per client and an expanded customer base [2][3]. Financial Highlights - Net revenue for fiscal 2024 reached $48.52 million, up from $28.23 million in 2023, marking a 72% increase [2][3][7]. - Gross profit increased by 33% to $2.75 million, compared to $2.06 million in the previous fiscal year [2][10]. - Net income grew by 33% to $1.29 million, up from $0.97 million in fiscal 2023 [2][13]. Revenue Generation - The company generates revenue through one-stop online marketing solutions, including traffic acquisition, content production, data analysis, and advertising campaign optimization [6]. - The increase in revenue is attributed to a rise in average revenue per client from $71,830 in fiscal 2023 to $89,355 in fiscal 2024, alongside an increase in the customer base from 393 to 543 clients [3][7]. Cost Structure - Cost of revenue increased by 75% to $45.77 million, in line with revenue growth [9][10]. - Selling and marketing expenses rose by 30% to $41,613, while general and administrative expenses increased by 17% to $911,531 [11][12]. Recent Developments - The company announced a strategic partnership with Gauss Intelligence to leverage AI capabilities for marketing solutions [4]. - A follow-on offering raised $12 million, enhancing the company's financial position [5]. Cash Position - As of June 30, 2024, the company had cash and cash equivalents of $6.66 million, a significant increase from $1.20 million in the previous year [13][18].

Core Insights - Haoxi Health Technology Limited (HAO) announced preliminary unaudited financial results for FY24, projecting significant revenue growth attributed to strategic developments in online advertising solutions, particularly in short video formats and news feed ads [1][2] Financial Performance - Revenue for FY24 is projected at approximately $48.52 million, reflecting a 72% increase from $28.23 million in FY23 [1] - Gross profit is estimated at approximately $2.75 million for FY24, a 33.4% increase from $2.06 million in FY23 [1] - Net income is projected to be approximately $1.29 million for FY24, marking a 33.2% increase from $0.97 million in FY23 [1] - Total assets increased to approximately $15.51 million as of June 30, 2024, up from $4.46 million at the end of FY23, indicating growth in operational scale and capital utilization post-IPO [1] Business Strategy and Market Position - Since its IPO in January 2024, HAO has consistently grown its core business, benefiting from the demand for targeted healthcare advertising in China [2] - The company aims to strengthen its position in the digital healthcare advertising market through established relationships with major media platforms and expertise in short video ad optimization [2] - HAO is committed to capitalizing on the expanding healthcare sector in China, focusing on ad placement strategies and enhancing service offerings [2][4]